dc
formul
involv
vivo
dc
target
readout
use
vivo
hepatotrop
adenoviru
challeng
histolog
autom
multidimension
fluoresc
microscopi
melc
show
target
vivo
antigen
deliveri
crosspres
dc
highli
effect
induc
antivir
ctl
capabl
elimin
virusinfect
hepatocyt
control
vaccin
formul
involv
dc
target
fail
induc
immun
hepatotrop
viru
moreov
observ
distinct
pattern
cell
interact
virusinfect
apoptot
hepatocyt
two
dctarget
group
suggest
differ
vaccin
formul
may
stimul
distinct
type
effector
function
find
repres
import
step
toward
futur
develop
vaccin
hepatotrop
virus
treatment
patient
hepat
viru
infect
liver
transplant
avoid
reinfect
liver
perman
expos
plethora
antigen
microbi
product
potenti
immunestimulatori
capac
predominantli
tolerogen
microenviron
liver
usual
prevent
induct
immun
innocu
antigen
time
favour
establish
persist
liver
infect
next
hepatotrop
virus
cytomegaloviru
cmv
hepat
b
viru
hbv
clinic
highli
relev
exampl
pathogen
capabl
establish
lifethreaten
chronic
infect
liver
hepat
c
viru
hcv
despit
extens
research
sinc
discoveri
hcv
effect
vaccin
still
avail
dendrit
cell
dc
repres
optim
target
design
effect
vaccin
dc
uniqu
respect
capac
effect
crosspres
exogen
antigen
mhci
molecul
induc
cytotox
cell
ctl
addit
respons
accordingli
dc
play
key
role
establish
antivir
immun
increas
knowledg
regard
characterist
pattern
recognit
receptor
prr
express
differ
dc
subset
set
basi
direct
target
antigen
vivo
mean
ligand
antibodi
specif
respect
prr
express
dc
context
particularli
tolllik
receptor
tlr
ctype
lectin
receptor
clr
gain
import
instanc
heterodim
agonist
propyl
rcysteinylamidomonomethoxyl
polyethylen
glycol
bppcysmpeg
synthet
deriv
macrophageactiv
lipopeptid
effect
target
crosspres
dc
importantli
coadministr
bppcysmpeg
togeth
solubl
ovalbumin
ova
ova
bppcysmpeg
result
induct
ovaspecif
ctl
interestingli
bppcysovampeg
compound
consist
immunodomin
ova
peptid
chemic
link
bppcysmpeg
therefor
specif
deliv
posit
dc
even
effect
induc
ovaspecif
ctl
next
heterodim
dc
express
high
level
clr
famili
endocytosi
receptor
importantli
receptormedi
antigen
uptak
dc
via
result
extraordinarili
effect
antigen
crosspresent
cell
steinman
colleagu
demonstr
vivo
target
antigen
crosspres
dc
mean
antibodyantigen
conjug
togeth
appropri
adjuv
result
potent
induct
specif
cell
respons
follow
studi
viral
bacteri
tumour
antigen
prove
antigen
deliveri
dc
elicit
protect
effector
cell
howev
studi
far
address
whether
antigen
deliveri
crosspres
dc
abl
induc
effector
cell
respons
antivir
immun
liver
improv
vaccin
efficaci
hepatotrop
virus
compar
differ
vaccin
formul
regard
potenc
induc
antivir
effector
cell
respons
liver
includ
target
antigen
deliveri
crosspres
dc
conjug
ova
protein
adjuv
poli
c
cpg
less
well
studi
bppcysovampeg
contain
two
immunodomin
mhci
ii
ova
peptid
assess
whether
antigen
target
dc
would
requir
induc
antivir
effector
cell
liver
anoth
group
receiv
ova
coadminist
bppcysmpeg
ova
bppcysmpeg
thu
involv
target
antigen
deliveri
dc
includ
show
immun
dc
target
formul
bppcysovampeg
ova
bppcysmpeg
vaccin
induc
effector
cell
capabl
elimin
viru
infect
hepatocyt
thu
conclud
target
vivo
antigen
deliveri
crosspres
dc
repres
promis
approach
induct
antivir
immun
liver
potenti
implic
develop
vaccin
hepatotrop
virus
target
antigen
dc
induc
humor
immun
first
compar
ovaspecif
humor
immun
respons
immun
either
adjuv
poli
c
cpg
poli
c
cpg
simplif
term
bppcysovampeg
addit
two
dc
target
approach
bppcysmpeg
coadminist
togeth
solubl
ova
ova
bppcysmpeg
control
includ
ova
alon
adjuv
poli
c
cpg
well
bppcysmpeg
alon
ova
peptid
alon
ova
peptid
adjuv
bppcysmpeg
alreadi
two
vaccin
observ
strong
ovaspecif
igg
respons
fig
significantli
increas
comparison
ova
bppcysmpeg
ova
poli
c
cpg
group
time
fig
mice
vaccin
novel
antigen
target
system
bppcysovampeg
initi
exhibit
weaker
igg
respons
howev
strongli
enhanc
follow
third
boost
fig
c
next
compar
ovaspecif
igg
igg
titr
repres
main
igg
isotyp
stimul
cell
respect
vaccin
either
ova
poli
c
cpg
bppcysovampeg
induc
rather
balanc
igg
igg
ratio
wherea
ova
bppcysmpeg
induc
substanti
higher
igg
igg
titr
point
toward
immun
respons
fig
expect
neither
inject
adjuv
bppcysmpeg
alon
vaccin
immunodomin
ova
peptid
without
adjuv
induc
humor
immun
moreov
peptid
target
dc
mean
vaccin
bppcysovampeg
superior
induc
antibodi
respons
vaccin
solubl
peptid
adjuv
bppcysmpeg
supplementari
fig
c
induct
ctl
follow
bppcysovampeg
immun
character
type
cell
respons
induc
differ
vaccin
formul
ovaspecif
secret
cell
evalu
ex
vivo
stimul
splenocyt
immun
mice
domin
ova
mhci
ii
peptid
expect
due
exclus
select
toward
epitop
immun
bppcysovampeg
highest
number
cytokin
produc
cell
observ
group
fig
bppcysovampeg
vaccin
induc
increas
number
cell
compar
ova
poli
c
cpg
immun
group
fig
compar
vaccin
formul
lack
direct
antigen
target
dc
bppcysovampeg
lesser
extent
immun
time
show
strongest
potenti
induc
produc
cell
fig
c
note
adjuv
bppcysmpeg
alon
vaccin
nonadjuv
immunodomin
ova
peptid
induc
produc
cell
furthermor
peptid
target
dc
use
bppcyovampeg
formul
induc
significantli
produc
cell
vaccin
mice
use
peptid
adjuv
bppcysmpeg
supplementari
fig
g
sinc
produc
ctl
import
viru
clearanc
liver
evalu
ovaspecif
ctl
activ
vaccin
mice
immun
bppcysovampeg
induc
robust
scientif
report
doi
ovaspecif
ctl
respons
alreadi
first
immun
fig
despit
fact
produc
cell
also
induc
ova
bppcysmpeg
immun
mice
fig
lysi
target
cell
detect
group
fig
thu
antigen
deliveri
dc
target
result
rather
weak
balanc
cell
respons
highli
effect
gener
antigenspecif
ctl
similarli
bppcysovampegmedi
antigen
target
induc
balanc
helper
robust
ovaspecif
ctl
respons
target
antigen
deliveri
dc
induc
memori
cell
liver
test
whether
ctl
induc
antigen
deliveri
dc
effect
recogn
elimin
viru
infect
hepatocyt
hepatotrop
adenoviru
challeng
model
util
fig
immun
mice
infect
recombin
adenoviru
adovagfpluc
lead
mhci
present
ova
peptid
infect
hepatocyt
furthermor
adovagfpluc
infect
cell
express
egfp
enhanc
green
fluoresc
protein
luciferas
allow
quantif
infect
fig
infect
oneway
anova
mean
sd
p
ovaspecif
serum
igg
igg
titr
day
statist
nonparametr
mann
whitney
test
compar
igg
igg
subclass
within
group
mean
sd
p
p
bar
repres
mean
sem
n
triplic
pool
anim
three
independ
experi
p
p
vivo
cytotox
assay
mice
n
immun
twice
thrice
histogram
cfse
splenocyt
one
repres
mous
per
group
per
point
time
bar
percentag
specif
lysi
mean
sem
statist
oneway
anova
p
p
p
mockimmun
mice
adovagfpluc
lead
accumul
high
cell
liver
accumul
intrahepat
high
cell
detect
experiment
group
follow
adovagfpluc
infect
fig
releas
ctl
shown
mediat
noncytolyt
clearanc
infect
hepatocyt
per
se
directli
inhibit
viral
replic
liver
hardli
product
detect
hepat
cell
fig
adovagfpluc
challeng
result
nearli
twofold
increas
proport
produc
high
cell
ova
bppcysmpeg
presenc
high
effector
cell
liver
correl
hepat
develop
follow
adovagfpluc
challeng
next
ask
whether
produc
effector
memori
cell
liver
would
respond
virusexpress
antigen
hepatocyt
adgfpluc
control
infect
induc
margin
hepatocellular
cell
death
cellular
infiltr
fig
infect
ovaimmun
group
adovagfpluc
led
drastic
histolog
lesion
liver
hepatocellular
cell
death
mark
infiltr
lymphocyt
macrophag
tissu
fig
c
sinc
histolog
score
reveal
trend
toward
enhanc
immunopatholog
liver
immun
adovagfpluc
infect
mice
compar
bppcysovampeg
group
elucid
whether
bppcysovampeg
vaccin
would
result
distinct
immun
cell
recruit
follow
viral
infect
howev
autom
multidimension
fluoresc
microscopi
melc
liver
section
reveal
signific
differ
hepat
composit
leukocyt
macrophag
neutrophil
nk
cell
b
cell
cell
subset
among
group
fig
b
supplementari
fig
altogeth
observ
type
immunopatholog
bppcysovampeg
immun
mice
indic
acut
hepat
consequ
immunemedi
clearanc
viru
infect
hepatocyt
suggest
antigenspecif
ctl
present
liver
follow
vaccin
account
hepatocyt
damag
vaccin
bppcysovampeg
result
effect
antigenspecif
viru
clearanc
liver
substanti
cytolyt
function
ctl
serum
concentr
alanin
transaminas
alt
determin
vaccin
adenoviruschalleng
anim
expect
infect
adgfpluc
control
viru
affect
serum
alt
level
experiment
group
fig
strikingli
well
bppcysovampeg
immun
mice
observ
dramat
compar
high
increas
serum
alt
level
ul
ui
respect
indic
massiv
ctlmediat
kill
adovagfpluc
infect
hepatocyt
fig
significantli
lower
alt
concentr
ul
measur
ova
bppcysmpeg
immun
mice
line
lower
abund
produc
memori
cell
fig
confirm
specif
kill
adovagfpluc
infect
hepatocyt
viru
clearanc
examin
assess
luciferas
express
liver
tissu
expect
strong
luciferas
activ
detect
liver
mice
infect
control
adgfpluc
viru
fig
contrast
luciferas
activ
liver
immun
adovagfpluc
infect
mice
significantli
reduc
bppcysovampeg
vaccin
mice
comparison
ova
bppcysmpeg
poli
c
cpg
mockimmun
anim
fig
taken
togeth
result
clearli
demonstr
antigen
target
crosspres
dc
either
bppcysovampeg
highli
effect
induc
effector
cell
capabl
recogn
elimin
viru
infect
hepatocyt
order
gain
first
indic
regard
underli
mechan
elimin
infect
hepatocyt
analys
liver
section
ova
bppcysovampeg
immun
adovagfpluc
infect
mice
potenti
differ
distanc
cell
viru
infect
hepatocyt
neither
observ
signific
differ
number
viru
infect
hepatocyt
number
hepatocyt
stain
posit
activ
fig
frequenc
cell
loos
contact
infect
hepatocyt
distanc
fig
inde
observ
significantli
fewer
cell
direct
contact
adovagfpluc
infect
hepatocyt
immun
mice
compar
bppcysovampeg
immun
group
fig
strikingli
despit
lower
abund
cell
intim
contact
viru
infect
cell
substanti
found
close
associ
activ
thu
apoptot
cell
liver
immun
mice
fig
togeth
observ
compar
bppcysovampeg
vaccin
immun
result
accumul
significantli
higher
frequenc
high
effector
cell
viru
infect
liver
fig
data
may
indic
two
differ
dctarget
formul
may
inde
stimul
distinct
type
effector
function
activ
viru
elimin
liver
show
vivo
antigen
deliveri
crosspres
dc
highli
effect
induc
antivir
immun
liver
bppcysovampeg
vaccin
includ
novel
antigen
target
system
exhibit
outstand
properti
induc
high
antibodi
titr
fig
cell
well
ctl
fig
effect
clear
viru
infect
hepatocyt
fig
although
reach
statist
signific
compar
vaccin
approach
tend
promot
robust
viral
clearanc
well
slightli
less
pronounc
hepatocellular
cell
death
proinflammatori
effect
valu
tlr
agonistantigen
conjug
induc
cell
respons
clearli
underscor
new
data
previou
studi
howev
clinic
applic
conjug
need
tailor
match
differ
hla
allel
rapidli
mutat
virus
eg
hcv
could
possibl
exploit
chemic
group
bppcysmpeg
gener
conjug
complex
antigen
engin
univers
dock
system
enabl
noncoval
bind
use
past
antibodi
prajeeth
et
al
shown
bppcysmpegmedi
activ
dc
led
effect
crossprim
coadminist
antigen
result
ctl
respons
spleen
detect
small
number
memori
cell
liver
ova
bppcysmpeg
immun
mice
follow
adovagfpluc
infect
fig
cell
exert
effector
function
fig
discrep
may
due
differ
antigen
concentr
use
mg
vs
g
howev
explan
yet
memori
cell
present
liver
ova
bppcysmpeg
immun
mice
exhibit
cytotox
function
strikingli
despit
lack
viral
erad
ova
bppcysmpeg
vaccin
group
mice
display
mark
immunopatholog
elev
alt
level
follow
adovagfpluc
infect
may
specul
although
function
impair
term
cytotox
antigenspecif
recognit
viru
cell
result
cytokin
releas
follow
innat
immun
activ
immun
cell
recruit
final
result
hepat
cell
death
inflamm
independ
ctl
mediat
kill
immun
induc
robust
ctl
respons
fig
result
effect
viral
clearanc
liver
fig
data
well
line
previou
studi
demonstr
vaccin
induc
cell
capabl
protect
tumour
viru
challeng
similar
result
obtain
target
tumour
viral
antigen
dc
next
ctl
respons
induc
immun
mice
detect
antigenspecif
cell
previou
studi
describ
preferenti
induct
respons
immun
observ
similar
level
cell
fig
b
consist
minor
differ
igg
subclass
fig
irrespect
antibodi
subclass
demonstr
comparison
formul
two
dc
target
approach
effect
induc
rapid
robust
humor
immun
respons
fig
hand
dc
target
approach
next
ctl
respons
induc
rather
balanc
profil
immun
ova
bppcysmpeg
involv
dc
target
fail
induc
ctl
result
domin
cytokin
profil
fig
interestingli
bppcysmpeg
shown
induc
immun
respons
context
allergen
parasit
antigen
howev
intramuscular
immun
hepat
b
surfac
antigen
viruslik
particl
coadminist
bppcysmpeg
result
domin
respons
therefor
adjuv
dose
rout
administr
intrins
featur
antigen
may
account
observ
differ
helper
cell
phenotyp
schulz
colleagu
prove
bppcysmpeg
potent
mucos
adjuv
vaccin
sever
acut
respiratori
syndrom
coronaviru
author
focus
cellular
humor
immun
respons
test
antivir
activ
thu
bppcysmpeg
investig
regard
potenc
induc
antivir
immun
absenc
dc
target
ie
use
ova
bppcysmpeg
formul
clearli
show
induct
cell
phenotyp
lack
ctl
consequ
antigenspecif
clearanc
viru
infect
hepatocyt
previou
studi
demonstr
except
potenti
antigen
target
elicit
adapt
immun
knowledg
first
studi
show
induct
liverspecif
immun
reaction
demonstr
target
dc
result
high
frequenc
local
memori
cell
fig
correl
protect
adenoviru
challeng
liver
fig
one
critic
point
fight
viral
infect
keep
balanc
protect
immun
immunopatholog
mainli
driven
ctl
often
decis
fate
infect
host
hepatotrop
virus
hcv
believ
directli
cytopath
liver
damag
attribut
cellmedi
immun
immunopatholog
inevit
steril
immun
hand
less
vigor
ctl
respons
allow
viral
persist
ultim
lead
progress
tissu
injuri
bppcysovampeg
group
could
immunopatholog
correl
antigenspecif
viral
clearanc
liver
fig
regard
sever
hepat
occur
side
effect
pathogen
elimin
highli
conceiv
bppcysovampeg
immun
mice
would
recov
liver
damag
publish
model
fulmin
hepat
failur
alt
level
peak
day
post
infect
endpoint
experi
studi
almost
normal
day
post
infect
howev
studi
need
evalu
consequ
immunemedi
hepat
term
clinic
applic
use
well
toler
adjuv
foremost
import
number
clinic
trial
indic
cpg
suffici
well
toler
poli
c
shown
exhibit
sever
side
effect
human
note
synthet
deriv
polyiclc
alreadi
success
use
target
trial
exhibit
better
resist
hydrolysi
well
greater
potenc
induc
secret
cell
poli
c
importantli
proven
safe
adjuv
healthi
human
volunt
cancer
patient
addit
studi
need
clarifi
whether
vaccin
use
polyiclccpg
adjuv
effici
even
effici
poli
c
cpg
vaccin
induc
antivir
immun
liver
regard
agonist
bppcysmpeg
known
activ
crossprim
dc
mice
far
publish
data
avail
clinic
applic
recent
shown
human
dc
thought
repres
function
equival
mous
dc
express
thu
interact
bppcysovampeg
dc
via
receptor
like
take
place
also
human
nevertheless
futur
vitro
studi
need
clarifi
issu
detail
observ
distinct
pattern
cell
interact
viru
infect
apoptot
hepatocyt
depend
vaccin
formul
use
fig
significantli
fewer
cell
intim
contact
viru
infect
hepatocyt
group
cell
appear
effect
induc
apoptosi
line
higher
express
marker
cytotox
potenti
well
establish
ctl
elimin
infect
hepatocyt
direct
antigen
recognit
target
cell
via
perforingranzym
fasmedi
kill
howev
cytotox
viru
infect
hepatocyt
also
exert
via
noncanon
ctl
effector
function
ctl
stimul
crosspres
liver
sinusoid
endotheli
cell
secret
tnf
stimul
tnf
induc
cell
death
specif
infect
hepatocyt
involv
activ
follow
tnfr
stimul
note
well
line
observ
elev
frequenc
ctl
adovagfpluc
infect
liver
compar
bppcysovampeg
immun
mice
overal
well
tnf
express
level
far
higher
treat
group
supplementari
fig
secret
highli
abund
ctl
may
account
elev
tnf
express
hepat
macrophag
adovagfpluc
infect
immun
mice
altern
shown
wohlleb
et
al
virusspecif
ctl
induc
may
sourc
tnf
investig
need
deciph
specif
mechan
underli
elimin
viru
infect
hepatocyt
bppcysovampeg
vaccin
mice
may
specul
immun
surveil
ova
immun
mice
addit
cellcontact
depend
ctlmediat
kill
higher
degre
involv
cytokinemedi
effector
function
first
line
tnf
may
import
cytokin
involv
elimin
viru
infect
hepatocyt
induc
apoptosi
adenoviru
infect
hepatocyt
although
shown
exert
noncytolyt
antivir
effector
function
hbv
infect
hepatocyt
previou
report
shown
ko
mice
behav
exactli
wildtyp
mice
regard
antivir
immun
respons
adenoviru
infect
hepatocyt
follow
liver
damag
exclud
high
level
may
enhanc
secondari
antivir
effect
exampl
upregul
antigenpresent
hepatocyt
enhanc
recognit
infect
cell
ctl
induct
antivir
immun
liver
per
se
challeng
issu
hallmark
eg
hcv
persist
appear
function
impair
exhaust
cell
unabl
secret
antivir
effector
molecul
show
impair
prolifer
dysregul
express
activatinginhibitori
receptor
next
patient
chronic
infect
hcv
higher
frequenc
suppress
regulatori
cell
like
contribut
cell
dysfunct
sinc
block
hold
therapeut
promis
function
recoveri
exhaust
cell
combin
strategi
encompass
antibodymedi
block
immunosuppress
pathway
togeth
boost
antivir
immun
mean
tlrmediat
antigen
deliveri
crosspres
dc
could
repres
promis
scenario
futur
develop
may
also
impli
use
dc
target
therapeut
vaccin
shown
clearli
effect
sever
studi
might
also
contribut
treatment
patient
hepat
viru
infect
liver
transplant
avoid
reinfect
mice
femal
mice
obtain
harlan
winkelmann
borchen
germani
hous
specif
pathogenfre
condit
accord
nation
institut
guidelin
experi
approv
local
govern
agenc
landesamt
verbraucherschutz
und
lebensmittelsicherheit
file
number
perform
accord
guidelin
antibodi
antigen
cell
line
endograd
conjug
ova
chemic
conjug
purifi
ova
perform
previous
publish
minor
modif
brief
first
activ
sulfosmcc
sulfosuccinimidyl
nmaleimidomethyl
thermo
fisher
scientif
usa
accord
manufactur
protocol
parallel
sulfhydrylgroup
ova
protein
expos
use
mm
tri
phosphin
hydrochlorid
tcephcl
thermo
fisher
scientif
usa
hour
room
temperatur
excess
tcep
sulfosmcc
respect
sampl
remov
use
zeba
desalt
spin
column
accord
manufactur
recommend
thermo
fisher
scientif
usa
reduc
ova
immedi
mix
activ
antibodi
incub
overnight
result
conjug
concentr
separ
unbound
ova
use
k
mwco
pierc
concentr
thermo
fisher
scientif
usa
quantif
ova
content
within
conjug
achiev
comparison
ova
signal
intens
western
blot
grade
quantiti
ova
blot
supplementari
fig
immun
mice
subcutan
immun
day
either
g
ova
g
g
bppcysovampeg
g
ova
coadminist
either
g
poli
c
g
cpg
previous
publish
g
bppcysmpeg
total
volum
l
pb
per
anim
determin
serum
alt
alt
quantif
l
peripher
blood
mix
l
heparin
ratiopharm
germani
centrifug
g
minut
room
temperatur
l
supernat
use
detect
alt
activ
use
scil
reflovet
plu
reflectionphotomet
scil
anim
care
germani
analysi
liver
lymphocyt
liver
perfus
icecold
pb
minc
ice
follow
enzymat
digest
imdm
gibco
germani
contain
mgml
collagenas
roch
germani
gml
dnase
sigma
germani
fc
minut
addit
edta
mm
final
concentr
cell
pellet
centrifug
minut
g
liver
lymphocyt
enrich
percol
densiti
gradient
centrifug
cell
stimul
mixtur
ova
protein
ova
peptid
gml
final
concentr
hour
cell
stimul
incub
gml
pma
sigma
germani
gml
ionomycin
sigma
germani
total
hour
gml
brefeldin
sigma
germani
ad
hour
flow
cytometr
analysi
fcblock
perform
incub
antimous
antibodi
follow
surfac
stain
mous
bd
bioscienc
ebiosci
fixat
paraformaldehydepb
vv
cell
permeabil
use
igep
sigma
germani
stain
intracellular
data
acquir
lsr
fortessa
instrument
bd
bioscienc
analys
use
flowjo
softwar
tree
star
usa
monitor
humor
immun
respons
l
blood
collect
retroorbit
sinu
serum
obtain
incub
sampl
minut
follow
minut
incub
subsequ
centrifug
minut
g
sera
assay
presenc
antigenspecif
igg
igg
subclass
igg
igg
enzymelink
immunosorb
assay
elisa
use
nuncimmuno
maxisorp
plate
nunc
germani
coat
gml
ova
protein
carbon
buffer
ph
overnight
incub
plate
wash
pb
supplement
tween
block
bsa
pb
hour
serial
dilut
sera
bsapb
ad
plate
incub
hour
wash
antibodi
bind
detect
use
biotinconjug
goat
mous
igg
sigma
germani
goat
mous
igg
southern
biotech
usa
goat
mous
igg
southern
biotech
usa
antibodi
hour
respect
streptavidinhrpo
bd
bioscienc
germani
minut
abt
citratephosph
buffer
ph
contain
h
ad
well
absorb
nm
record
minut
incub
endpoint
titr
express
reciproc
valu
last
serum
dilut
yield
absorb
two
time
valu
neg
control
ebiosci
germani
bd
bioscienc
germani
use
accord
manufactur
instruct
spot
count
elispot
reader
ctl
europ
gmbh
germani
analys
use
immunospot
imag
analys
softwar
ctl
europ
gmbh
germani
result
present
spot
form
unit
per
cell
vivo
cytotox
assay
splenocyt
isol
naiv
syngen
donor
mice
equal
cell
number
puls
gml
siinfekl
ova
peptid
minut
room
temperatur
left
untreat
follow
label
cfse
high
cfse
low
cfse
respect
mix
one
one
ratio
total
target
cell
intraven
iv
inject
recipi
mice
one
day
splenocyt
reisol
ratio
cfse
high
cfse
low
label
cell
determin
flow
cytometri
use
fac
canto
instrument
bd
bioscienc
germani
adenoviru
challeng
assay
day
first
immun
mice
infect
intraven
plaqu
form
unit
pfu
recombin
adenoviru
express
fusion
protein
either
gfp
luciferas
adgfpluc
gfp
luciferas
ova
siinfekl
adovagfpluc
control
anim
receiv
pb
either
mockinfect
pb
infect
adovagfpluc
luciferas
activ
assay
lower
liver
lobe
separ
two
part
weigh
tissu
fragment
homogen
proport
volum
report
lysi
buffer
promega
germani
use
lyse
matrix
mp
biomed
germani
instrument
sec
msec
centrifug
minut
g
lysat
mix
luciferas
assay
reagent
ii
promega
germani
measur
luminomet
berthold
technolog
germani
liver
tissu
poli
c
cpg
bppcysovampeg
immun
mice
snap
frozen
embed
oct
sakura
finetek
liver
sampl
bppcysovampeg
mice
display
compar
alt
level
case
analys
melc
robot
parallel
cryosect
thick
adher
silanco
cover
slide
prepar
leica
cryostat
fix
paraformaldehyd
santa
cruz
permeabil
block
bsapb
sigma
h
detail
inform
imag
acquisit
analysi
describ
supplementari
materi
optim
antibodi
dilut
incub
time
posit
within
melc
experi
antibodi
use
see
supplementari
tabl
valid
systemat
use
condit
suitabl
melc
see
supplementari
figur
left
upper
liver
lobe
fix
formaldehyd
solut
follow
paraffin
embed
prepar
section
stain
haematoxylin
eosin
h
e
histolog
evalu
perform
anim
pathologist
certifi
american
colleg
veterinari
pathologist
blind
fashion
statist
analys
result
statist
analys
oneway
anova
follow
dunnett
test
twoway
rm
anova
nonparametr
mann
whitney
test
pair
twotail
ttest
use
graph
pad
prism
softwar
graph
pad
softwar
la
jolla
data
present
mean
sem
mean
sd
pvalu
consid
signific
